Company Overview
About Colossal Biosciences
Colossal Biosciences is the world's first commercial de-extinction and genomic engineering company, applying CRISPR gene editing and synthetic biology to resurrect extinct species and restore ecological balance. Founded in 2021 by tech entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal is simultaneously pursuing the de-extinction of the woolly mammoth, the Tasmanian thylacine, the dodo bird, the dire wolf, and the bluebuck antelope — building the scientific and technological infrastructure to produce living specimens of each. The company's Dallas, Texas headquarters anchors a multi-disciplinary team spanning computational biology, developmental biology, reproductive science, and conservation ecology.
Business Model & Competitive Advantage
Colossal secured $200M in Series C funding in January 2025, bringing its total raise to $555M and its valuation to $10.2 billion — making it Texas' first decacorn. In March 2025, Colossal announced the creation of three gene-edited dire wolf pups, produced using cloning and targeted gene editing to express dire wolf traits within a closely related extant canid genome. The company is on track to produce woolly mammoth embryos by end of 2026, using Asian elephant cells modified with 58 mammoth-specific genetic variants, with ambitions to re-wild cold-adapted mammoth analogs to Siberian steppe ecosystems by the end of the decade.
Competitive Landscape 2025–2026
Beyond the headline species, Colossal's work generates commercially valuable genetic tools: its biobank and gene editing techniques have applications in species conservation, synthetic biology, pharmaceutical discovery, and materials science. The company operates Colossal Genomics, a bioinformatics division, and has attracted investors including Thomas Tull, Tony Robbins, and Bold Capital Partners — alongside scientific advisors from leading universities and conservation organizations. A September 2025 raise of $120M added momentum to its dodo and bluebuck programs.
Key Differentiators
Emerging Innovator
Colossal Biosciences is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Colossal Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Colossal Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Colossal Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Colossal Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →